step 6 semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Semaglutide: The Drug of Today

Our study examined male and female human samples, as reported in Supplementary Table 1, and similar findings are reported for both sexes

severe chronic heart failure

Deal trajectory: Novo paid $200M upfront to license a triple agonist (UBT251) from United Laboratories (China) in March 2025 directly targeting the same GLP-1/GIP/GCGR space as Lillys retatrutide

Significantly more tirzepatide patients hit every major weight loss milestone, including 10%, 15%, 20%, and 25% body weight reduction

Instead, focus on small portions of complex, high-fibre carbohydrates

#PublicPolicy #BiotechRegulation #DrugSafety #Ibogaine To view or add a comment, sign in FDA classifies Xanax XR recall after anxiety drug failed dissolution testing: The FDA classified the voluntary recall as Class II, meaning temporary adverse health consequences are possible To view or add a comment, sign in Patients who develop visual problems while taking a GLP-1 receptor agonist should stop the drug, a drug safety expert says